Cat. No：GM-C30574
Product ：H_CD80 PDL1 aAPC CHO-K1 Cell Line
Cat. No：GM-C30574
Product ：H_CD80 PDL1 aAPC CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+4 μg/mL Puromycin+ 100 μg/mL Hygromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells, playing a crucial role in regulating immune responses to tumors and self-antigens. The interaction of PD-1 on neighboring cells with its ligands PD-L1 or PD-L2 inhibits the transmission of TCR signaling pathways, as well as TCR-mediated cell proliferation, transcription activation, and cytokine production effects. Therapeutic antibodies and Fc fusion proteins targeting PD-1/PD-L1 interactions have shown promising applications in clinical trials for treating various cancers.
CTLA-4, also known as CD152, is an immune inhibitory receptor expressed constitutively on regulatory T cells (Tregs), playing a key role in regulating immune responses. When CTLA-4 expression on T cell surfaces is upregulated, T cells bind with higher affinity to CD80 (B7-1) or CD86 (B7-2) than CD28's positive co-stimulatory signal, inducing T cell unresponsiveness. Research has indicated that antibodies and Fc fusion proteins blocking CTLA-4/CD80 and CD86 interactions have shown good prospects in clinical trials for treating a variety of cancers.
Clinical data has shown that the combined use of CTLA-4 and PD-1 antibodies, or the use of CTLA-4/PD-1 bispecific antibodies, has better treatment outcomes compared to using single CTLA-4 or PD-1 antibodies.
The Genomeditech H CTLA4 PD-1 Reporter Cell Line is a stable cell line expressing CTLA-4 and PD-1 luciferase reporter genes. When co-cultured with H_CD80 PDL1 aAPC CHO-K1 Cell Line (Genomeditech/GM-C30574), it inhibits TCR downstream signaling in the presence of CTLA-4 blocking CD28 from binding with CD80 and PD-1/PD-L1 interactions. Following the addition of CTLA-4, PD-1, or CTLA-4/PD-1 bispecific antibodies, blocking CTLA-4/PD-1 restores TCR signaling, and the Luciferase readout reflects the activation effect of the signaling pathway. This cell line can be used for in vitro evaluation of CTLA-4/PD-1-related drugs.
| CTLA4:CD80:CD86 | ||
| Raji Cell Line | Canine_CD80 aAPC CHO-K1 Cell Line | Canine_CTLA4 Reporter Jurkat Cell Line |
| H_CD80 aAPC CHO-K1 Cell Line | H_CTLA4 PD-1 Reporter Cell Line | H_CTLA4 Reporter Jurkat Cell Line |
| Canine_CTLA4 CHO-K1 Cell Line | Cynomolgus_CTLA4 HEK-293 Cell Line | H_CTLA4 CHO-K1 Cell Line |
| H_CTLA4 HEK-293 Cell Line | H_CTLA4 Jurkat Cell Line | |
| Anti-Canine_CTLA4 mIgG2a Antibody(A1mut2) | Anti-CTLA4 hIgG1 Reference Antibody (Ipibio) | Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab) |
| Anti-H_CD80 hIgG1 Antibody(Galiximab) | Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab) | Anti-mouse CTLA4 mIgG2a Antibody(9D9) |
| Biotinylated Mouse CTLA4 Protein; His-Avi Tag | Mouse CTLA4 Protein; His Tag | |
Cat. No：GM-C30574
Product ：H_CD80 PDL1 aAPC CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+4 μg/mL Puromycin+ 100 μg/mL Hygromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells, playing a crucial role in regulating immune responses to tumors and self-antigens. The interaction of PD-1 on neighboring cells with its ligands PD-L1 or PD-L2 inhibits the transmission of TCR signaling pathways, as well as TCR-mediated cell proliferation, transcription activation, and cytokine production effects. Therapeutic antibodies and Fc fusion proteins targeting PD-1/PD-L1 interactions have shown promising applications in clinical trials for treating various cancers.
CTLA-4, also known as CD152, is an immune inhibitory receptor expressed constitutively on regulatory T cells (Tregs), playing a key role in regulating immune responses. When CTLA-4 expression on T cell surfaces is upregulated, T cells bind with higher affinity to CD80 (B7-1) or CD86 (B7-2) than CD28's positive co-stimulatory signal, inducing T cell unresponsiveness. Research has indicated that antibodies and Fc fusion proteins blocking CTLA-4/CD80 and CD86 interactions have shown good prospects in clinical trials for treating a variety of cancers.
Clinical data has shown that the combined use of CTLA-4 and PD-1 antibodies, or the use of CTLA-4/PD-1 bispecific antibodies, has better treatment outcomes compared to using single CTLA-4 or PD-1 antibodies.
The Genomeditech H CTLA4 PD-1 Reporter Cell Line is a stable cell line expressing CTLA-4 and PD-1 luciferase reporter genes. When co-cultured with H_CD80 PDL1 aAPC CHO-K1 Cell Line (Genomeditech/GM-C30574), it inhibits TCR downstream signaling in the presence of CTLA-4 blocking CD28 from binding with CD80 and PD-1/PD-L1 interactions. Following the addition of CTLA-4, PD-1, or CTLA-4/PD-1 bispecific antibodies, blocking CTLA-4/PD-1 restores TCR signaling, and the Luciferase readout reflects the activation effect of the signaling pathway. This cell line can be used for in vitro evaluation of CTLA-4/PD-1-related drugs.
| CTLA4:CD80:CD86 | ||
| Raji Cell Line | Canine_CD80 aAPC CHO-K1 Cell Line | Canine_CTLA4 Reporter Jurkat Cell Line |
| H_CD80 aAPC CHO-K1 Cell Line | H_CTLA4 PD-1 Reporter Cell Line | H_CTLA4 Reporter Jurkat Cell Line |
| Canine_CTLA4 CHO-K1 Cell Line | Cynomolgus_CTLA4 HEK-293 Cell Line | H_CTLA4 CHO-K1 Cell Line |
| H_CTLA4 HEK-293 Cell Line | H_CTLA4 Jurkat Cell Line | |
| Anti-Canine_CTLA4 mIgG2a Antibody(A1mut2) | Anti-CTLA4 hIgG1 Reference Antibody (Ipibio) | Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab) |
| Anti-H_CD80 hIgG1 Antibody(Galiximab) | Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab) | Anti-mouse CTLA4 mIgG2a Antibody(9D9) |
| Biotinylated Mouse CTLA4 Protein; His-Avi Tag | Mouse CTLA4 Protein; His Tag | |
